Compare VENUS REMEDIES with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES PANACEA BIOTECH VENUS REMEDIES/
PANACEA BIOTECH
 
P/E (TTM) x -1.0 12.2 - View Chart
P/BV x 0.1 2.9 2.5% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   PANACEA BIOTECH
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
PANACEA BIOTECH
Mar-18
VENUS REMEDIES/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs126364 34.6%   
Low Rs61129 47.3%   
Sales per share (Unadj.) Rs301.896.8 311.8%  
Earnings per share (Unadj.) Rs-24.9-12.4 200.4%  
Cash flow per share (Unadj.) Rs2.5-2.9 -89.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.350.4 581.9%  
Shares outstanding (eoy) m12.3461.25 20.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.5 12.2%   
Avg P/E ratio x-3.8-19.9 18.9%  
P/CF ratio (eoy) x36.7-86.4 -42.5%  
Price / Book Value ratio x0.34.9 6.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,15415,101 7.6%   
No. of employees `0000.92.5 37.5%   
Total wages/salary Rs m3931,516 25.9%   
Avg. sales/employee Rs Th4,026.12,401.9 167.6%   
Avg. wages/employee Rs Th425.0614.2 69.2%   
Avg. net profit/employee Rs Th-331.8-307.9 107.7%   
INCOME DATA
Net Sales Rs m3,7245,928 62.8%  
Other income Rs m2382 27.3%   
Total revenues Rs m3,7476,010 62.3%   
Gross profit Rs m395845 46.7%  
Depreciation Rs m338585 57.8%   
Interest Rs m3541,006 35.2%   
Profit before tax Rs m-275-664 41.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m02 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3299 32.0%   
Profit after tax Rs m-307-760 40.4%  
Gross profit margin %10.614.3 74.3%  
Effective tax rate %-11.5-14.9 77.2%   
Net profit margin %-8.2-12.8 64.3%  
BALANCE SHEET DATA
Current assets Rs m2,6385,603 47.1%   
Current liabilities Rs m2,3056,910 33.4%   
Net working cap to sales %8.9-22.0 -40.6%  
Current ratio x1.10.8 141.1%  
Inventory Days Days135206 65.8%  
Debtors Days Days4684 55.3%  
Net fixed assets Rs m4,8719,941 49.0%   
Share capital Rs m12361 201.3%   
"Free" reserves Rs m3,4963,026 115.5%   
Net worth Rs m3,6193,087 117.2%   
Long term debt Rs m1,3745,707 24.1%   
Total assets Rs m7,50916,076 46.7%  
Interest coverage x0.20.3 65.5%   
Debt to equity ratio x0.41.8 20.5%  
Sales to assets ratio x0.50.4 134.5%   
Return on assets %0.61.5 41.3%  
Return on equity %-8.5-24.6 34.4%  
Return on capital %1.63.9 40.4%  
Exports to sales %024.0 0.0%   
Imports to sales %13.917.5 79.1%   
Exports (fob) Rs mNA1,424 0.0%   
Imports (cif) Rs m5171,040 49.7%   
Fx inflow Rs m01,600 0.0%   
Fx outflow Rs m5171,131 45.6%   
Net fx Rs m-517469 -110.2%   
CASH FLOW
From Operations Rs m5141,180 43.6%  
From Investments Rs m-123553 -22.3%  
From Financial Activity Rs m-387-1,644 23.6%  
Net Cashflow Rs m490 4.7%  

Share Holding

Indian Promoters % 32.9 74.5 44.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.6 30.0%  
FIIs % 0.6 1.3 44.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 23.6 281.4%  
Shareholders   20,121 10,259 196.1%  
Pledged promoter(s) holding % 36.4 35.1 103.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 20, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - JUBILANT LIFE SCIENCES COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS